Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

United States Antimony Corporation

UAMY
Materials · Other Industrial Metals & Mining

United States Antimony Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.

The price is between stages. Underneath, the last four quarters read mixed. What settles it: the next one or two quarters of delivery.

Price
$6.1
+106.8% 1Y
Revenue (Mar 26)
$0.0 B
+0.0% YoY
Profit (Mar 26)
$−0.0 B
Operating margin
−100.0%
−100.0 pp YoY
ROE
−20%
FY25
ROIC
−14.5%
vs WACC 6.5% → −21.0 pp
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

United States Antimony Corporation trades at $6.1, between stages. That is −24.4% against its own 200-day average. It sits at 23% of a 52-week range of $4 to $12. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (11 weeks and counting).

Today the stock is between stages. At $6.1 it trades −24.4% versus its 200-day average and sits at 23% of its 52-week range ($4–$12).

Aug 26: $6.1 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 1-year window.
−24.4% versus the 200-day line, week — of stage —
Price50-day avg200-day avg
$13.0$10.2$7.5$4.7$2.0$$6$8Jul 25Oct 25Jan 26May 26Aug 26
$13.0$10.2$7.5$4.7$2.0$$6$8Jul 25Jan 26Aug 26
Beating or trailing, week by week since 2025 Each cell is one week from 2025 to now (57 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 25Aug 26

Against the market, two honest reads. Cumulative: over the last 1.1 years the stock moved +125% while the S&P 500 moved +24% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (11 weeks and counting; last ahead the week of 2026-05-22) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

P/E does not price United States Antimony Corporation — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values United States Antimony Corporation at 25.0× its FY25 revenue of $0.0 B.

With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.

P/E
earnings negative
PEG
n/m
not derivable — 3-year earnings growth unavailable

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

United States Antimony Corporation reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 1 curve, on partial evidence.

Growth, year by year: revenue +300.0% in FY25 Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoY
324%237%150%63%−24%%300%FY21FY23FY25
324%237%150%63%−24%%300%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from
RevenueEPS
316%−192%258%−221%200%−250%142%−279%84%−308%%%100%−300%Jun 23Sep 24Mar 26
316%−192%258%−221%200%−250%142%−279%84%−308%%%100%−300%Jun 23Sep 24Mar 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
2.7%−7.0%−17%−26%−36%%−11.1%Jun 23Dec 23Sep 24Jun 25Mar 26
2.7%−7.0%−17%−26%−36%%−11.1%Jun 23Sep 24Mar 26
ROCE
Falling
latest −11.1% · span −33.3%–0.0%

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+300.0%+58.7%
Stock price+106.8%
Revenue YoY (Mar 26)
+0.0%
latest quarter vs a year ago
Revenue 10y
41.4%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

33.3/100 — rank 11 of 30 in Other Industrial Metals & Mining · 58% evidence confidence

United States Antimony Corporation scores 33.3 out of 100 against the 30 companies it is compared with in Other Industrial Metals & Mining, ranking 11. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 13.4 + 5.5 + 9.1 + 5.3 = 33.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

United States Antimony Corporation reported $0.0 B of revenue in the Mar 26 quarter, +0.0% year on year. Over 4 years it has compounded at 41.4% a year. The last full year, FY25, came in at $0.0 B. The last four reported quarters add to $0.0 B.

FY25 revenue came in at $0.0 B (+300.0% on the year), capping 4 years at 41.4% compound. The latest quarter (Mar 26) printed $0.0 B, +0.0% year on year.

FY25 revenue $0.0 B (+300.0% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
41.4% a year over 4 years
RevenueYoY growth
0.04324%0.03237%0.02150%0.0163%0.00−24%$ B%$0B300%FY21FY23FY25
0.04324%0.03237%0.02150%0.0163%0.00−24%$ B%$0B300%FY21FY23FY25
Mar 26: $0.0 B (+0.0% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
0.0111.2%0.0080.6%0.0050.0%0.003−0.6%0.000−1.2%$ B%$0B0%Jun 23Sep 24Mar 26
0.0111.2%0.0080.6%0.0050.0%0.003−0.6%0.000−1.2%$ B%$0B0%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +0.0% growth against the decade's 41.4% — the current year is running slower than its own long-run rate.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

United States Antimony Corporation's operating margin is −100.0% in the Mar 26 quarter, −100.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −100.0% to 0.0%. The current quarter sits inside that band.

The latest quarter's operating margin is −100.0%, −100.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −100.0%–0.0%.

🚨 Why the margin moved: operating margin went −100.0 pp year on year while gross margin went +0.0 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY25: −25.0% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a −100.0–0.0% band over 5 years
operating marginYoY change (pp)
8.0%116%−21%58%−50%0.0%−79%−58%−108%−116%%%−25%−25%FY21FY23FY25
8.0%116%−21%58%−50%0.0%−79%−58%−108%−116%%%−25%−25%FY21FY23FY25
Mar 26: −100.0% operating margin (−100.0 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
8.0%8.0%−21%−21%−50%−50%−79%−79%−108%−108%%%−100%−100%Jun 23Sep 24Mar 26
8.0%8.0%−21%−21%−50%−50%−79%−79%−108%−108%%%−100%−100%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

United States Antimony Corporation posted a net loss of $0.01 B in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. That loss is 100.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 1 of the last 12 reported quarters were loss-making.

Mar 26 profit was $−0.0 B, null year on year. On the full year, FY25 printed $0.0 B (null).

FY25 profit $0.0 B (null YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profit
0.001−0.002−0.005−0.008−0.011$ B$0BFY21FY23FY25
0.001−0.002−0.005−0.008−0.011$ B$0BFY21FY23FY25
Mar 26: $−0.0 B (null YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)
0.001−0.002−0.005−0.008−0.011$ B$0BJun 23Sep 24Mar 26
0.001−0.002−0.005−0.008−0.011$ B$0BJun 23Sep 24Mar 26
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

United States Antimony Corporation's cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $−0.0 B of operating cash against $0.0 B of profit. After $0.0 B of capital spending, $−0.0 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.

FY25: operating cash of $−0.0 B against reported profit of $0.0 B, leaving free cash of $−0.0 B after $0.0 B of capital spending.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $−0.0 B vs profit $0.0 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution. FY25 reflects an acquisition year — point shown clipped.
Operating cashNet profitFree cash
0.001−0.002−0.005−0.008−0.011$ B$0B$0B$0BFY21FY23FY25
0.001−0.002−0.005−0.008−0.011$ B$0B$0B$0BFY21FY23FY25
Mar 26: operating cash $−0.0 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)100%
0.001101.2%−0.002100.6%−0.005100.0%−0.00899.4%−0.01198.8%$ B%$0BJun 23Sep 24Mar 26
0.001101.2%−0.002100.6%−0.005100.0%−0.00899.4%−0.01198.8%$ B%$0BJun 23Sep 24Mar 26

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

United States Antimony Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

FY25: capex $0.0 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.0320.0240.0160.0080.000$ B$0BFY21FY23FY25
0.0320.0240.0160.0080.000$ B$0BFY21FY23FY25
Mar 26: capex $0.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.0110.0020.008−0.0040.005−0.0100.003−0.0160.000−0.022$ B$ B$0B$0BJun 23Sep 24Mar 26
0.0110.0020.008−0.0040.005−0.0100.003−0.0160.000−0.022$ B$ B$0B$0BJun 23Sep 24Mar 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

United States Antimony Corporation earns a ROE of 0% in FY25. That is up from a trough of −33% in FY23. Return on invested capital clears the cost of that capital by −21.0 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 0.0% net margin on 0.27× asset turns.

FY25 ROE is 0%, recovered from a FY23 trough of −33% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY25): 0.0% net margin × 0.27× asset turns × 1.07× balance-sheet leverage ≈ 0.0% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: −14.5% − 6.5% = a −21.0 pp spread. The 6.5% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

FY25: ROE 0% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 6.5% cost of capital used on this page.
the climb back from FY23's −33%
ROEROIC (annual)WACC
11%−6.1%−23%−41%−58%%0%−14.4%FY21FY23FY25
11%−6.1%−23%−41%−58%%0%−14.4%FY21FY23FY25
Mar 26: ROIC −6.5% (TTM) vs WACC 6.5% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
11%−4.2%−19%−34%−48%%−6.5%−13.7%Jun 23Sep 24Mar 26
11%−4.2%−19%−34%−48%%−6.5%−13.7%Jun 23Sep 24Mar 26
11 · Dividend

Dividend

United States Antimony Corporation pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

United States Antimony Corporation does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

United States Antimony Corporation carries total debt of $0.0 B against shareholder equity of $0.1 B as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.00 in FY21 to 0.00 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of $0.0 B against shareholder equity of $0.1 B — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.00 (FY21) to 0.00 (FY25). The returns on this page are earned, not borrowed.

FY25: debt $0.0 B at 0.00× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
1.21.2×0.60.6×0.00.0×−0.6−0.6×−1.2−1.2×$ B×$0B0.00×FY21FY23FY25
1.21.2×0.60.6×0.00.0×−0.6−0.6×−1.2−1.2×$ B×$0B0.00×FY21FY23FY25
Mar 26: debt $0.0 B, debt-to-equity 0.00 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
1.21.2×0.60.6×0.00.0×−0.6−0.6×−1.2−1.2×$ B×$0B0.00×Jun 23Sep 24Mar 26
1.21.2×0.60.6×0.00.0×−0.6−0.6×−1.2−1.2×$ B×$0B0.00×Jun 23Sep 24Mar 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

23.7% of United States Antimony Corporation's tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 4.7 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 23.7% of the float is sold short, and at typical trading volumes it would take about 4.7 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
23.7%
of the tradable float
Days to cover
4.7
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

United States Antimony Corporation: the Z-score reads 28.92. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 28.92 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 28.92.

15 · Related companies · Other Industrial Metals & Mining
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Santacruz Silver Mining Ltd.SCZM 65.6/100Favorable setup81% evidence ASLEEP 23.7/35 Revenue 28% · PAT 46.3% · OPM change -5.3 pp 83% evidence 19.6/25 ROCE 30.1% · OPM 26.6% 76% evidence 15.2/20 P/E 13× · PEG 0.36 65% evidence 7.1/20 RS sector -12.6% · RS bench -18.7% · 1Y 78.7%0 of 12 weeks ahead 100% evidence
Exact sum: 23.7 + 19.6 + 15.2 + 7.1 = 65.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Teck Resources LimitedTECK 65.4/100Thin evidence · provisional58% evidence ASLEEP 22.2/35 Revenue — · PAT — · OPM change 19.3 pp 45% evidence 14.9/25 ROCE 3.9% · OPM 41.2% 76% evidence 9.8/20 P/E 16.6× · PEG — 15% evidence 18.5/20 RS sector 22.4% · RS bench 14.9% · 1Y 96%3 of 12 weeks ahead 100% evidence
Exact sum: 22.2 + 14.9 + 9.8 + 18.5 = 65.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
3Nexa Resources S.A.NEXA 61.6/100Thin evidence · provisional58% evidence FADING 20.8/35 Revenue 16% · PAT — · OPM change 14.8 pp 62% evidence 13.4/25 ROCE 5.5% · OPM 23.4% 76% evidence 10.7/20 P/E 6.7× · PEG — 15% evidence 16.7/20 RS sector 33.8% · RS bench 21.2% · 1Y 177.2%6 of 12 weeks ahead 70% evidence
Exact sum: 20.8 + 13.4 + 10.7 + 16.7 = 61.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
4Almonty Industries Inc.ALM 58.2/100Thin evidence · provisional55% evidence ASLEEP 24.2/35 Revenue 72.4% · PAT — · OPM change 87.5 pp 62% evidence 10.3/25 ROCE 1% · OPM 14% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 13.7/20 RS sector 11.5% · RS bench -0.9% · 1Y 222.3%1 of 12 weeks ahead 70% evidence
Exact sum: 24.2 + 10.3 + 10 + 13.7 = 58.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
5Vale S.A.VALE 56.9/100Thin evidence · provisional58% evidence ASLEEP 20.1/35 Revenue — · PAT — · OPM change 3.5 pp 45% evidence 15.0/25 ROCE 5.5% · OPM 25.7% 76% evidence 9.4/20 P/E 30.7× · PEG — 15% evidence 12.4/20 RS sector 1.4% · RS bench -4.7% · 1Y 45.1%0 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 15 + 9.4 + 12.4 = 56.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
6Materion CorporationMTRN 55.9/100Thin evidence · provisional58% evidence LEADER 15.2/35 Revenue — · PAT — · OPM change -3.4 pp 45% evidence 12.1/25 ROCE 1.8% · OPM 5.1% 76% evidence 9.0/20 P/E 40.7× · PEG — 15% evidence 19.6/20 RS sector 35.4% · RS bench 27.1% · 1Y 113.3%12 of 12 weeks ahead 100% evidence
Exact sum: 15.2 + 12.1 + 9 + 19.6 = 55.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7Americas Gold and Silver CorporationUSAS 55.5/100Thin evidence · provisional55% evidence ASLEEP 24.6/35 Revenue 58.3% · PAT — · OPM change 87.3 pp 62% evidence 15.0/25 ROCE 11.6% · OPM 39.9% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 5.9/20 RS sector -16.8% · RS bench -24.1% · 1Y 60.8%0 of 12 weeks ahead 70% evidence
Exact sum: 24.6 + 15 + 10 + 5.9 = 55.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8Compass Minerals International, Inc.CMP 55.1/100Thin evidence · provisional58% evidence FADING 19.0/35 Revenue 6.4% · PAT — · OPM change 13 pp 62% evidence 11.5/25 ROCE 4.8% · OPM 12.4% 76% evidence 8.5/20 P/E 155.7× · PEG — 15% evidence 16.1/20 RS sector 21.9% · RS bench 15.2% · 1Y 39%11 of 12 weeks ahead 70% evidence
Exact sum: 19 + 11.5 + 8.5 + 16.1 = 55.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9Ferroglobe PLCGSM 42.0/100Thin evidence · provisional58% evidence BASING 18.7/35 Revenue -11.8% · PAT — · OPM change 15.9 pp 62% evidence 9.1/25 ROCE -0.8% · OPM -2.2% 76% evidence 9.3/20 P/E 31.7× · PEG — 15% evidence 4.9/20 RS sector -26.9% · RS bench -29.4% · 1Y -15.6%0 of 12 weeks ahead 70% evidence
Exact sum: 18.7 + 9.1 + 9.3 + 4.9 = 42 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
10MP Materials Corp.MP 35.0/100Mixed-negative evidence64% evidence ASLEEP 14.0/35 Revenue 18.1% · PAT — · OPM change -16 pp 62% evidence 8.1/25 ROCE -2.3% · OPM -73.2% 76% evidence 8.7/20 P/E 141.8× · PEG — 15% evidence 4.2/20 RS sector -28.1% · RS bench -29.6% · 1Y -36.1%2 of 12 weeks ahead 100% evidence
Exact sum: 14 + 8.1 + 8.7 + 4.2 = 35 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11United States Antimony Corporationthis pageUAMY 33.3/100Thin evidence · provisional58% evidence ASLEEP 13.4/35 Revenue 100% · PAT — · OPM change -115.9 pp 62% evidence 5.5/25 ROCE -8.9% · OPM -110.8% 76% evidence 9.1/20 P/E 36.8× · PEG — 15% evidence 5.3/20 RS sector -23% · RS bench -28.1% · 1Y 68.1%1 of 12 weeks ahead 70% evidence
Exact sum: 13.4 + 5.5 + 9.1 + 5.3 = 33.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12BHP Group LimitedBHP 60.7/100Thin evidence · provisional38% evidence ASLEEP 17.9/35 Revenue — · PAT — · OPM change — 9% evidence 14.2/25 ROCE 6.5% · OPM — 46% evidence 9.9/20 P/E 15× · PEG — 15% evidence 18.7/20 RS sector 21.1% · RS bench 14.4% · 1Y 65.5%3 of 12 weeks ahead 100% evidence
Exact sum: 17.9 + 14.2 + 9.9 + 18.7 = 60.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13Rio Tinto GroupRIO 58.8/100Thin evidence · provisional43% evidence ASLEEP 17.7/35 Revenue — · PAT — · OPM change — 12% evidence 13.8/25 ROCE 4.1% · OPM — 61% evidence 10.4/20 P/E 12.9× · PEG — 15% evidence 16.9/20 RS sector 12.1% · RS bench 5.3% · 1Y 60.1%2 of 12 weeks ahead 100% evidence
Exact sum: 17.7 + 13.8 + 10.4 + 16.9 = 58.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14Evolution Metals & Technologies Corp.EMAT 52.8/100Thin evidence · provisional34% evidence ASLEEP 17.9/35 Revenue — · PAT — · OPM change — 4% evidence 14.8/25 ROCE 276.6% · OPM -332.9% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 10.1/20 RS sector 0.1% · RS bench -9.1% · 1Y -73.6%0 of 12 weeks ahead 70% evidence
Exact sum: 17.9 + 14.8 + 10 + 10.1 = 52.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
15Sigma Lithium CorporationSGML 52.4/100Thin evidence · provisional50% evidence ASLEEP 21.2/35 Revenue — · PAT — · OPM change 18.4 pp 39% evidence 14.1/25 ROCE 8% · OPM 32.6% 76% evidence 8.8/20 P/E 109.4× · PEG — 15% evidence 8.3/20 RS sector -3.6% · RS bench -12.5% · 1Y 104%4 of 12 weeks ahead 70% evidence
Exact sum: 21.2 + 14.1 + 8.8 + 8.3 = 52.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Elevra Lithium LimitedELVR 50.7/100Thin evidence · provisional15% evidence ASLEEP 16.5/35 Revenue — · PAT — · OPM change — 9% evidence 14.2/25 ROCE 12.6% · OPM — 46% evidence 10.0/20 P/E — · PEG — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y —5 of 12 weeks ahead 0% evidence
Exact sum: 16.5 + 14.2 + 10 + 10 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17Lithium Argentina AGLAR 50.1/100Thin evidence · provisional44% evidence ASLEEP 18.3/35 Revenue — · PAT — · OPM change — 33% evidence 10.8/25 ROCE 1.2% · OPM — 61% evidence 11.3/20 P/E 0.4× · PEG — 15% evidence 9.7/20 RS sector -0.4% · RS bench -9.6% · 1Y 128.5%6 of 12 weeks ahead 70% evidence
Exact sum: 18.3 + 10.8 + 11.3 + 9.7 = 50.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
18NioCorp Developments Ltd.NB 47.4/100Thin evidence · provisional44% evidence ASLEEP 21.1/35 Revenue — · PAT — · OPM change — 33% evidence 8.7/25 ROCE -3.1% · OPM — 61% evidence 11.0/20 P/E 3.6× · PEG — 15% evidence 6.6/20 RS sector -15.4% · RS bench -18.4% · 1Y 9.5%0 of 12 weeks ahead 70% evidence
Exact sum: 21.1 + 8.7 + 11 + 6.6 = 47.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
19Skeena Resources LimitedSKE 45.2/100Thin evidence · provisional47% evidence ASLEEP 15.1/35 Revenue — · PAT — · OPM change — 33% evidence 6.7/25 ROCE -5% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 13.4/20 RS sector 4.2% · RS bench -3.6% · 1Y 76.8%0 of 12 weeks ahead 100% evidence
Exact sum: 15.1 + 6.7 + 10 + 13.4 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
20Blue Moon Metals Inc.BMM 44.5/100Thin evidence · provisional44% evidence ASLEEP 12.2/35 Revenue — · PAT — · OPM change — 33% evidence 5.7/25 ROCE -15.7% · OPM — 61% evidence 11.2/20 P/E 2.7× · PEG — 15% evidence 15.4/20 RS sector 20.4% · RS bench 9.2% · 1Y 113.5%5 of 12 weeks ahead 70% evidence
Exact sum: 12.2 + 5.7 + 11.2 + 15.4 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
21IperionX LimitedIPX 42.1/100Thin evidence · provisional41% evidence ASLEEP 19.8/35 Revenue — · PAT — · OPM change — 33% evidence 9.0/25 ROCE 0% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 3.3/20 RS sector -43% · RS bench -44.2% · 1Y -37.2%1 of 12 weeks ahead 70% evidence
Exact sum: 19.8 + 9 + 10 + 3.3 = 42.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
22Critical Metals Corp.CRML 41.3/100Thin evidence · provisional37% evidence ASLEEP 17.9/35 Revenue — · PAT — · OPM change — 24% evidence 7.6/25 ROCE -14.6% · OPM — 46% evidence 11.5/20 P/E 0× · PEG — 15% evidence 4.3/20 RS sector -33.9% · RS bench -38.4% · 1Y 46.4%3 of 12 weeks ahead 70% evidence
Exact sum: 17.9 + 7.6 + 11.5 + 4.3 = 41.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
23TMC the metals company Inc.TMC 41.2/100Thin evidence · provisional50% evidence ASLEEP 20.3/35 Revenue — · PAT — · OPM change — 33% evidence 5.4/25 ROCE -49.4% · OPM — 61% evidence 10.9/20 P/E 5.9× · PEG — 15% evidence 4.6/20 RS sector -37% · RS bench -39.2% · 1Y -29.7%0 of 12 weeks ahead 100% evidence
Exact sum: 20.3 + 5.4 + 10.9 + 4.6 = 41.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
24Lithium Americas Corp.LAC 39.8/100Thin evidence · provisional41% evidence ASLEEP 16.5/35 Revenue — · PAT — · OPM change — 33% evidence 9.7/25 ROCE -0.6% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 3.6/20 RS sector -37.7% · RS bench -40.7% · 1Y 10.4%0 of 12 weeks ahead 70% evidence
Exact sum: 16.5 + 9.7 + 10 + 3.6 = 39.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
25Trilogy Metals Inc.TMQ 39.7/100Thin evidence · provisional41% evidence ASLEEP 14.9/35 Revenue — · PAT — · OPM change — 33% evidence 8.3/25 ROCE -1.7% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 6.5/20 RS sector -14.5% · RS bench -20.8% · 1Y 126.3%0 of 12 weeks ahead 70% evidence
Exact sum: 14.9 + 8.3 + 10 + 6.5 = 39.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
26REalloys Inc.ALOY 39.6/100Thin evidence · provisional43% evidence TURNING 11.2/35 Revenue — · PAT — · OPM change -96.5 pp 39% evidence 5.2/25 ROCE -155.8% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 13.2/20 RS sector 6.1% · RS bench -1.8% · 1Y 66.8%5 of 12 weeks ahead 70% evidence
Exact sum: 11.2 + 5.2 + 10 + 13.2 = 39.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27Vizsla Silver Corp.VZLA 38.4/100Thin evidence · provisional41% evidence BASING 14.5/35 Revenue — · PAT — · OPM change — 33% evidence 8.3/25 ROCE -2.4% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 5.6/20 RS sector -22.5% · RS bench -25% · 1Y 3.7%0 of 12 weeks ahead 70% evidence
Exact sum: 14.5 + 8.3 + 10 + 5.6 = 38.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
28Northern Dynasty Minerals Ltd.NAK 37.8/100Thin evidence · provisional44% evidence ASLEEP 12.9/35 Revenue — · PAT — · OPM change — 33% evidence 6.7/25 ROCE -12.4% · OPM — 61% evidence 10.6/20 P/E 7.2× · PEG — 15% evidence 7.6/20 RS sector -9.6% · RS bench -15.8% · 1Y 77.8%7 of 12 weeks ahead 70% evidence
Exact sum: 12.9 + 6.7 + 10.6 + 7.6 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29USA Rare Earth, Inc.USAR 37.1/100Thin evidence · provisional45% evidence ASLEEP 17.0/35 Revenue — · PAT -1061% · OPM change — 7% evidence 6.2/25 ROCE -3.4% · OPM -643.6% 76% evidence 9.6/20 P/E 17× · PEG — 15% evidence 4.3/20 RS sector -14.1% · RS bench -18.7% · 1Y 6.2%6 of 12 weeks ahead 100% evidence
Exact sum: 17 + 6.2 + 9.6 + 4.3 = 37.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
30Standard Lithium Ltd.SLI 36.0/100Thin evidence · provisional50% evidence ASLEEP 17.0/35 Revenue — · PAT -127.6% · OPM change — 33% evidence 8.9/25 ROCE -0.9% · OPM — 61% evidence 10.1/20 P/E 13.2× · PEG — 15% evidence 0.0/20 RS sector -44.4% · RS bench -47.2% · 1Y -22.2%0 of 12 weeks ahead 100% evidence
Exact sum: 17 + 8.9 + 10.1 + 0 = 36 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is United States Antimony Corporation's stock price today?

United States Antimony Corporation trades at $6.1, +106.8% over the past year. The company is valued at $1.0 B. The stock sits at 23% of its 52-week range of $4–$12, −24.4% versus its 200-day average. Against the S&P 500 it has been behind on a trailing-13-week view for 11 weeks. — as of 5 August 2026.

What were United States Antimony Corporation's latest quarterly results?

United States Antimony Corporation reported revenue of $0.0 B and a net loss of $0.0 B for the Mar 26 quarter. Earnings per share were $−0.08. The operating margin was −100.0%, 100.0 pp lower than a year earlier. — as of 5 August 2026.

What is United States Antimony Corporation's revenue?

United States Antimony Corporation reported revenue of $0.0 B in the Mar 26 quarter, +0.0% year on year. For the full FY25 fiscal year, revenue was $0.0 B (+300.0%). Over the last 4 years revenue compounded at 41.4% a year. — as of 5 August 2026.

What is United States Antimony Corporation's profit?

United States Antimony Corporation earned $−0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. The operating margin ran −100.0% in the latest quarter. — as of 5 August 2026.

What is United States Antimony Corporation's market cap?

United States Antimony Corporation's market capitalisation is $1.0 B at a stock price of $6.1. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

Does United States Antimony Corporation pay a dividend?

No — United States Antimony Corporation has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.

How is United States Antimony Corporation performing?

United States Antimony Corporation's latest readings are below. Against the S&P 500 it has been behind on a trailing-13-week view for 11 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

Is United States Antimony Corporation beating the market?

Not lately — on a trailing-13-week view United States Antimony Corporation is currently behind the S&P 500 (11 weeks and counting; last ahead the week of 2026-05-22), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.1 years the stock moved +125% against the S&P 500's +24% — ahead of the index over the full window. — as of 5 August 2026.

Will United States Antimony Corporation's stock price go up?

This page publishes no price forecast for United States Antimony Corporation. What it measures instead: the stock price is $6.1. Direction is not something this site claims to know. — as of 5 August 2026.

Is the market betting against United States Antimony Corporation?

Yes — short interest is 23.7% of United States Antimony Corporation's tradable float, about 4.7 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

What is United States Antimony Corporation's capex?

United States Antimony Corporation spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.

What is United States Antimony Corporation's cash flow?

United States Antimony Corporation generated $−0.0 B of operating cash flow in FY25 and $−0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran behind profit. — as of 5 August 2026.

How financially safe is United States Antimony Corporation?

On the balance sheet, the Z-score reads 28.92 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.

Where is United States Antimony Corporation in its business cycle?

United States Antimony Corporation's FY25 operating margin was −25.0%, against a 5-year band of −100.0%–0.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran −100.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the United States Antimony Corporation story?

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is United States Antimony Corporation a stock worth studying right now?

This is not investment advice. The machine read: United States Antimony Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI